论文部分内容阅读
目的对浙江省低危固定成分献血者队伍建设策略进行系统性评价。方法建立固定成分献血者队伍建设策略,包括成分献血者精准招募、献血环境改善、献血流程优化、成分献血服务规范提升、成分全过程整体护理、个性化机采方案制定、成分献血全过程宣教、关爱激励机制建立等措施,对2012-2015年固定成分献血者人数、人次、年献血频次(年献血频次=人次/人数)和血液检测结果使用SPSS 19.0统计软件包进行数据分析。结果固定成分献血者人数由2012年1 278人增加至2015年1 922人,构成比由16.0%上升至29.7%(P<0.001),固定献血人次由7112人次增加至14440人次,构成比从48.2%上升至72.8%(P<0.001);成分献血者年均献血次数由2.22次/年上升至3.06次/年,固定献血者由6.46次/年上升至7.51次/年;2012-2015年固定、重复和初次献血者的血液检测阳性率分别为0.234%、0.672%和1.48%(P<0.001)。结论固定成分献血者队伍建设策略是成分献血长效机制的重要组成部分,是保障机采血小板稳定、充足、安全供应的基石。
Objective To systematically evaluate the construction strategy of low-risk fixed-constituent blood donor team in Zhejiang Province. Methods The establishment of fixed-component blood donors construction strategy, including the precise recruitment of blood donors, the improvement of blood donation, the optimization of blood donation, the improvement of blood donation services, the overall nursing of whole ingredients, the formulation of personalized harvesting plans, Care incentives and other measures to measure the number of blood donors, persons, annual blood donation frequency (annual blood donation frequency = person / person) and blood test results from 2012 to 2015 using SPSS 19.0 statistical software package for data analysis. Results The number of blood donors with fixed components increased from 1,278 in 2012 to 1,922 in 2015, with the ratio increasing from 16.0% to 29.7% (P <0.001), and the number of fixed blood donations increased from 7112 to 14,440, accounting for 48.2% % To 72.8% (P <0.001). The annual blood donations of constituent blood donors increased from 2.22 times per year to 3.06 times per year, and the number of fixed blood donors increased from 6.46 times to 7.51 times per year. In 2012-2015, The positive rates of blood tests in repeat and primary blood donors were 0.234%, 0.672% and 1.48%, respectively (P <0.001). Conclusion The construction strategy of fixed-component blood donor team is an important part of long-term mechanism of blood donation and is the cornerstone of stable, adequate and safe supply of platelet.